Sepsis related mortality of extremely low gestational age newborns after the introduction of colonization screening for multi-drug resistant organisms.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
26 08 2020
Historique:
received: 11 04 2020
accepted: 12 08 2020
entrez: 27 8 2020
pubmed: 28 8 2020
medline: 3 9 2021
Statut: epublish

Résumé

In 2013 German infection surveillance guidelines recommended weekly colonization screening for multidrug-resistant (MDRO) or highly epidemic organisms for neonatal intensive care units (NICUs) and extended hygiene measures based on screening results. It remains a matter of debate whether screening is worth the effort. We therefore aimed to evaluate sepsis related outcomes before and after the guideline update. The German Neonatal Network (GNN) is a prospective cohort study including data from extremely preterm infants between 22 + 0 and 28 + 6 gestational weeks born in 62 German level III NICUs. Infants treated after guideline update (n = 8.903) had a lower mortality (12.5% vs. 13.8%, p = 0.036), reduced rates for clinical sepsis (31.4 vs. 42.8%, p <  0.001) and culture-proven sepsis (14.4% vs. 16.5%, p = 0.003) as compared to infants treated before update (n = 3.920). In a multivariate logistic regression analysis, nine pathogens of culture-proven sepsis were associated with sepsis-related death, e.g. Pseudomonas aeruginosa [OR 59 (19-180), p <  0.001)]. However, the guideline update had no significant effect on pathogen-specific case fatality, total sepsis-related mortality and culture-proven sepsis rates with MDRO. While the exposure of GNN infants to cefotaxime declined over time (31.1 vs. 40.1%, p <  0.001), the treatment rate with meropenem was increased (31.6 vs. 26.3%, p <  0.001). The introduction of weekly screening and extended hygiene measures is associated with reduced sepsis rates, but has no effects on sepsis-related mortality and sepsis with screening-relevant pathogens. The high exposure rate to meropenem should be a target of antibiotic stewardship programs.

Sections du résumé

BACKGROUND
In 2013 German infection surveillance guidelines recommended weekly colonization screening for multidrug-resistant (MDRO) or highly epidemic organisms for neonatal intensive care units (NICUs) and extended hygiene measures based on screening results. It remains a matter of debate whether screening is worth the effort. We therefore aimed to evaluate sepsis related outcomes before and after the guideline update.
METHODS
The German Neonatal Network (GNN) is a prospective cohort study including data from extremely preterm infants between 22 + 0 and 28 + 6 gestational weeks born in 62 German level III NICUs.
RESULTS
Infants treated after guideline update (n = 8.903) had a lower mortality (12.5% vs. 13.8%, p = 0.036), reduced rates for clinical sepsis (31.4 vs. 42.8%, p <  0.001) and culture-proven sepsis (14.4% vs. 16.5%, p = 0.003) as compared to infants treated before update (n = 3.920). In a multivariate logistic regression analysis, nine pathogens of culture-proven sepsis were associated with sepsis-related death, e.g. Pseudomonas aeruginosa [OR 59 (19-180), p <  0.001)]. However, the guideline update had no significant effect on pathogen-specific case fatality, total sepsis-related mortality and culture-proven sepsis rates with MDRO. While the exposure of GNN infants to cefotaxime declined over time (31.1 vs. 40.1%, p <  0.001), the treatment rate with meropenem was increased (31.6 vs. 26.3%, p <  0.001).
CONCLUSIONS
The introduction of weekly screening and extended hygiene measures is associated with reduced sepsis rates, but has no effects on sepsis-related mortality and sepsis with screening-relevant pathogens. The high exposure rate to meropenem should be a target of antibiotic stewardship programs.

Identifiants

pubmed: 32843080
doi: 10.1186/s13756-020-00804-8
pii: 10.1186/s13756-020-00804-8
pmc: PMC7449086
doi:

Substances chimiques

Anti-Bacterial Agents 0
Meropenem FV9J3JU8B1
Cefotaxime N2GI8B1GK7

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144

Références

Clin Microbiol Infect. 2018 Mar;24(3):251-257
pubmed: 28830807
Arch Dis Child Fetal Neonatal Ed. 2013 Nov;98(6):F549-53
pubmed: 23792354
J Pediatr. 2018 Oct;201:106-114.e4
pubmed: 30054165
Klin Padiatr. 2013 Mar;225(2):75-80
pubmed: 23526612
Neonatology. 2017;112(3):267-273
pubmed: 28704818
Infection. 2019 Aug;47(4):557-564
pubmed: 30607897
Pediatr Infect Dis J. 2017 Aug;36(8):774-779
pubmed: 28709162
Arch Dis Child Fetal Neonatal Ed. 2020 Mar;105(2):190-195
pubmed: 31248963
PLoS One. 2012;7(6):e38304
pubmed: 22768043
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651
N Engl J Med. 2017 Feb 16;376(7):617-628
pubmed: 28199816
Pediatr Infect Dis J. 2019 Sep;38(9):952-957
pubmed: 31274834
Semin Fetal Neonatal Med. 2016 Dec;21(6):388-393
pubmed: 27345372
Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F293-F297
pubmed: 29954881
Pediatrics. 2016 Apr;137(4):
pubmed: 26956103
J Hosp Infect. 2018 Aug;99(4):367-380
pubmed: 29577993
Pediatrics. 2017 Dec;140(6):
pubmed: 29162660
Pediatr Infect Dis J. 1995 May;14(5):367-71
pubmed: 7638011
PLoS One. 2019 Nov 22;14(11):e0225407
pubmed: 31756213
Arch Dis Child Fetal Neonatal Ed. 2018 Nov;103(6):F547-F553
pubmed: 29208666
Infect Control Hosp Epidemiol. 2016 Aug;37(8):924-30
pubmed: 27143176
Neonatology. 2013;103(2):155-60
pubmed: 23235260
Arch Dis Child Fetal Neonatal Ed. 2016 Jan;101(1):F72-8
pubmed: 26369370
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753

Auteurs

Christoph Härtel (C)

Department of Pediatrics, University of Lübeck, Lübeck, Germany. haertel_c1@ukw.de.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany. haertel_c1@ukw.de.
German Neonatal Network (GNN), Lübeck, Germany. haertel_c1@ukw.de.
Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany. haertel_c1@ukw.de.
Department of Pediatrics, University of Würzburg, Josef-Schneider-Strasse 2, D-97080, Würzburg, Germany. haertel_c1@ukw.de.

Kirstin Faust (K)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.

Ingmar Fortmann (I)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Alexander Humberg (A)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.

Julia Pagel (J)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.

Clara Haug (C)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Reinhard Kühl (R)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Pediatrics, Diakonissenkrankenhaus, Flensburg, Germany.

Bettina Bohnhorst (B)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Neonatology, Hannover Medical School, Hannover, Germany.

Sabine Pirr (S)

Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.
Department of Neonatology, Hannover Medical School, Hannover, Germany.

Dorothee Viemann (D)

Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.
Department of Neonatology, Hannover Medical School, Hannover, Germany.

Arne Simon (A)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Pediatrics, Saar University Homburg, Homburg, Germany.

Michael Zemlin (M)

German Neonatal Network (GNN), Lübeck, Germany.
Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.
Department of Pediatrics, Saar University Homburg, Homburg, Germany.

Silvia Poralla (S)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Pediatrics, University of Bonn, Bonn, Germany.

Andreas Müller (A)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Pediatrics, University of Bonn, Bonn, Germany.

Natascha Köstlin-Gille (N)

Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany.

Christian Gille (C)

German Neonatal Network (GNN), Lübeck, Germany.
Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.
Department of Neonatology, Tuebingen University Children's Hospital, Tuebingen, Germany.

Matthias Heckmann (M)

German Neonatal Network (GNN), Lübeck, Germany.
Department of Neonatology and Pediatric Intensive Care, University of Greifswald, Greifswald, Germany.

Jan Rupp (J)

German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.
Department of Infectious Diseases and Medical Microbiology, University of Lübeck, Lübeck, Germany.

Egbert Herting (E)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
German Neonatal Network (GNN), Lübeck, Germany.
Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.

Wolfgang Göpel (W)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
German Neonatal Network (GNN), Lübeck, Germany.
Priming Immunity at the beginning of life (PRIMAL) Consortium, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH